Key Highlights

  • Actuate shares were trading up 4.66% at $0.37, against a prior close of $0.35.
  • Oral elraglusib significantly inhibited tumor growth in an aggressive melanoma model.
  • The treatment increased CD8+ T cell and natural killer cell accumulation in tumors.
  • A Phase 1/2 trial of the oral tablet is planned for the first quarter of 2027.
  • The data will be presented at the ENA 2026 symposium in Barcelona.

Preclinical Melanoma Data Give Shares a Small Lift

Actuate (NASDAQ:ACTU) shares were trading up 4.66% at $0.37 on Wednesday, against a prior close of $0.35, after the company announced new preclinical data for the oral tablet formulation of elraglusib. The stock sits near the bottom of a 52-week range of $0.33 to $7.90, so the gain is small against a large decline.

The data will be shown in a poster at the ENA 2026 symposium, held November 18 to 20 in Barcelona.

What the Mouse Study Showed

In a poorly immunogenic, fast-growing B16F10 melanoma model, daily oral elraglusib significantly slowed tumor growth and was well tolerated. Tumor analysis showed more CD8+ T cells and natural killer cells and fewer myeloid-like suppressor cells, which suggests the treatment shifts the tumor environment toward a more active immune state.

The company describes this as the first in vivo evidence of both direct antitumor and immune effects of the oral tablet in a mouse model with a working immune system.

Next Step: A Phase 1/2 Trial in 2027

Chief Executive Daniel Schmitt said the work supports the mechanism of action. Actuate plans a Phase 1/2 trial of the oral tablet in the first quarter of 2027. The company is based in Fort Worth, Texas, has about 12 employees and is also running a Phase 2 program in metastatic pancreatic cancer, where mid-stage data were reported in April.

Early-Stage Data, Penny Stock Risk

Mouse results often Fail to carry over to patients, and the company will need new funding to carry out its plans. At under $1, the stock carries the usual penny stock risks.